Copyright
©The Author(s) 2024.
World J Clin Cases. Mar 26, 2024; 12(9): 1585-1596
Published online Mar 26, 2024. doi: 10.12998/wjcc.v12.i9.1585
Published online Mar 26, 2024. doi: 10.12998/wjcc.v12.i9.1585
Figure 1 Wharton’s Jelly–derived mesenchymal stem cell flow cytometry, positive marker values (CD90, CD105, CD73 and CD44) are above 95%.
Negative marker values (CD45, CD34, CD19, CD11B, human leukocyte antigen-DR and CD14) are below 2%. HLA: Human leukocyte antigen.
- Citation: Boyalı O, Kabatas S, Civelek E, Ozdemir O, Bahar-Ozdemir Y, Kaplan N, Savrunlu EC, Karaöz E. Allogeneic mesenchymal stem cells may be a viable treatment modality in cerebral palsy. World J Clin Cases 2024; 12(9): 1585-1596
- URL: https://www.wjgnet.com/2307-8960/full/v12/i9/1585.htm
- DOI: https://dx.doi.org/10.12998/wjcc.v12.i9.1585